Default company panoramic image
993868c6 1366 444b 8dbb 413092e00edf


OncoMark has developed a novel prognostic test for breast cancer that identifies those patients who do not require chemotherapy, a market worth €1.1BN.

  • Stage Product In Development
  • Industry Medical Devices and Equipment
  • Location Dublin, Ireland
  • Currency EUR
  • Founded January 2007
  • Employees 8
  • Website

Company Summary

OncoMark has licenced a proven technology with excellent proof of concept data, which was developed by leading scientists in TCD & UCD. The company will fast-track product development (aiming for CE marking in 2.5 years), aided by a prestigious EU Horizon 2020 SME instrument grant starting in Feb 2016. The development has a clear regulatory & reimbursement pathway, resulting in a premium test with significant margin and return of investment.